Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
Identifieur interne : 000500 ( Main/Exploration ); précédent : 000499; suivant : 000501Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
Auteurs : Tanya Simuni [États-Unis] ; Emily Borushko [États-Unis] ; Michael J. Avram [États-Unis] ; Scott Miskevics [États-Unis] ; Audrey Martel [États-Unis] ; C. Zadikoff [États-Unis] ; Aleksandar Videnovic [États-Unis] ; Frances M. Weaver [États-Unis] ; Karen Williams [États-Unis] ; D. James Surmeier [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-12-15.
English descriptors
Abstract
Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty‐one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23308
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study</title><author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name></author><author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name></author><author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name></author><author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name></author><author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name></author><author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name></author><author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name></author><author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name></author><author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name></author><author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9AE1202002DDA6F5C7F465D199F30A35B6F16867</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23308</idno><idno type="url">https://api.istex.fr/document/9AE1202002DDA6F5C7F465D199F30A35B6F16867/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002803</idno><idno type="wicri:Area/Main/Curation">002458</idno><idno type="wicri:Area/Main/Exploration">000500</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study</title><author><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hines VA Hospital, Hines, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hines VA Hospital, Hines, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-12-15">2010-12-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="2863">2863</biblScope><biblScope unit="page" to="2866">2866</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9AE1202002DDA6F5C7F465D199F30A35B6F16867</idno><idno type="DOI">10.1002/mds.23308</idno><idno type="ArticleID">MDS23308</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinical trial</term><term>dihydropyridine calcium channel blockers</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent data suggests that isradipine, a dihydropyridine calcium channel blocker, is neuroprotective in preclinical models of parkinsonism. Isradipine has not been systematically studied in patients with Parkinson's disease (PD). The aim of this study was to evaluate safety and tolerability of isradipine controlled release (CR) in patients with early PD. Qualified subjects (n = 31) received isradipine CR, titrated from 5 to 20 mg daily dose over 8 weeks as tolerated. Eighty‐one percent of subjects completed the study. Tolerability of isradipine CR was dose dependent: 94% for 5 mg dose; 87% for 10 mg; 68% for 15 mg; and 52% for 20 mg. Isradipine had no significant effect on blood pressure or PD motor disability. The two most common reasons for dose reduction were leg edema (7) and dizziness (3). There was no difference in isradipine tolerability between subjects with and without dopaminergic treatment, or with and without hypertension. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Simuni, Tanya" sort="Simuni, Tanya" uniqKey="Simuni T" first="Tanya" last="Simuni">Tanya Simuni</name></region><name sortKey="Avram, Michael J" sort="Avram, Michael J" uniqKey="Avram M" first="Michael J." last="Avram">Michael J. Avram</name><name sortKey="Borushko, Emily" sort="Borushko, Emily" uniqKey="Borushko E" first="Emily" last="Borushko">Emily Borushko</name><name sortKey="Martel, Audrey" sort="Martel, Audrey" uniqKey="Martel A" first="Audrey" last="Martel">Audrey Martel</name><name sortKey="Miskevics, Scott" sort="Miskevics, Scott" uniqKey="Miskevics S" first="Scott" last="Miskevics">Scott Miskevics</name><name sortKey="Surmeier, D James" sort="Surmeier, D James" uniqKey="Surmeier D" first="D. James" last="Surmeier">D. James Surmeier</name><name sortKey="Videnovic, Aleksandar" sort="Videnovic, Aleksandar" uniqKey="Videnovic A" first="Aleksandar" last="Videnovic">Aleksandar Videnovic</name><name sortKey="Weaver, Frances M" sort="Weaver, Frances M" uniqKey="Weaver F" first="Frances M." last="Weaver">Frances M. Weaver</name><name sortKey="Williams, Karen" sort="Williams, Karen" uniqKey="Williams K" first="Karen" last="Williams">Karen Williams</name><name sortKey="Zadikoff, C" sort="Zadikoff, C" uniqKey="Zadikoff C" first="C." last="Zadikoff">C. Zadikoff</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000500 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000500 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9AE1202002DDA6F5C7F465D199F30A35B6F16867
|texte= Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
}}
| This area was generated with Dilib version V0.6.23. |  |